glp 1 and macular degeneration Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists decrease retinal GLP-1 RAs Linked to Doubled

According to estimates on reported 2017 sales and data collected by IQVIA, Victoza accounted for market shares of ~48%, 58%, 49%, 41%, 75%, and 68%, in North America, Europe, Africa, Asia, the Middle East and Oceania, Japan and Korea, Latin America, and China, respectively

Thus, the affordability, accessibility, and efficacy of these drugs have led financial analysts to predict that the GLP-1RA market will exceed $100 billion by 2030

Learn more Why it matters: For many patients, the biggest barrier to consistency is not motivationits logistics

OpenLoop Healthcare Partners, PC is the licensed medical group that employs or contracts the licensed providers who evaluate your intake form and, when appropriate in their independent clinical judgment, issue prescriptions for GLP-1 medication

Future Drivers of Access in Europe The aforementioned influences on the US payer landscape are also likely to impact market access in Europe

About this GLP1s and vision loss research news Author: Patti Zielinski Source: Rutgers University Contact: Patti Zielinski Rutgers University Image: The image is credited to Neuroscience News Original Research: Open access